- Sweden
- /
- Medical Equipment
- /
- OM:EKTA B
Elekta's (STO:EKTA B) Shareholders Will Receive A Bigger Dividend Than Last Year
Elekta AB (publ) (STO:EKTA B) will increase its dividend from last year's comparable payment on the 2nd of March to SEK1.20. This will take the dividend yield to an attractive 3.2%, providing a nice boost to shareholder returns.
See our latest analysis for Elekta
Elekta's Dividend Is Well Covered By Earnings
Impressive dividend yields are good, but this doesn't matter much if the payments can't be sustained. Before this announcement, Elekta was paying out 111% of what it was earning, and not generating any free cash flows either. This high of a dividend payment could start to put pressure on the balance sheet in the future.
Looking forward, earnings per share is forecast to rise by 135.8% over the next year. Under the assumption that the dividend will continue along recent trends, we think the payout ratio could be 56% which would be quite comfortable going to take the dividend forward.
Dividend Volatility
Although the company has a long dividend history, it has been cut at least once in the last 10 years. The dividend has gone from an annual total of SEK1.00 in 2013 to the most recent total annual payment of SEK2.40. This implies that the company grew its distributions at a yearly rate of about 9.1% over that duration. We like to see dividends have grown at a reasonable rate, but with at least one substantial cut in the payments, we're not certain this dividend stock would be ideal for someone intending to live on the income.
There Isn't Much Room To Grow The Dividend
With a relatively unstable dividend, it's even more important to see if earnings per share is growing. We are encouraged to see that Elekta has grown earnings per share at 5.2% per year over the past five years. Although per-share earnings are growing at a credible rate, the massive payout ratio may limit growth in the company's future dividend payments.
The Dividend Could Prove To Be Unreliable
Overall, we always like to see the dividend being raised, but we don't think Elekta will make a great income stock. The track record isn't great, and the payments are a bit high to be considered sustainable. We don't think Elekta is a great stock to add to your portfolio if income is your focus.
It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. However, there are other things to consider for investors when analysing stock performance. Case in point: We've spotted 2 warning signs for Elekta (of which 1 can't be ignored!) you should know about. Is Elekta not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks.
Valuation is complex, but we're here to simplify it.
Discover if Elekta might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:EKTA B
Elekta
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide.
Undervalued with reasonable growth potential.